This deal will more than triple Aphria’s production capacity of medical cannabis from 9,000 kg to 30,000 kg annually.
Canadian marijuana company, Aphria, (TSX: APH and US OTC: APHQF) said on Tuesday that its medical marijuana production is expected to increase more than threefold after receiving a license amendment from Health Canada.
The license will provide Aphria with additional production space of 200,000 square feet, as part of its third-tier expansion at its facility in Leamington, Ontario.
“This marks the completion of the third part of our four-part expansion plan and is another exciting milestone for Aphria,” said Vic Neufeld, Chief Executive Office of Aphria.
The first crop cultivated and produced at third-phase expansion will be available for sale in the last week of May.